SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor

Leukemia

Volumn 13, Issue 9, 1999, Pages 1374-1382

  Marchetto, S ^a   Fournier, E ^a   Beslu, N ^a   Aurran Schleinitz, T ^a   Dubreuil, P ^a   Borg, J P ^a   Birnbaum, D ^a   Rosnet, O ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

FLT3; Phosphotyrosine; PTB domain; SH2 domain; SHC; SHIP

Indexed keywords

CYTOPLASM PROTEIN; PHOSPHOPROTEIN; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE; REGULATOR PROTEIN;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 0032846420     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401527     Document Type: Article

References (52)

1. Lyman S, Jacobsen S. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
2. Shaw S, Maung A, Steptoe R, Thomson A, Vujanovic N. Expansion of functional NK cells in multiple tissue compartment of mice treated with Flt3-ligand; implication for anti-cancer and anti-viral therapy. J Immunol 1998; 161: 2817-2824.
3. Maraskovsky E, Brasel K, Teepe M, Roux E, Lyman S, Shortman K, McKenna H. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 3: 147-161.
4. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller R, Schuh J. Flt3 ligand induces tumor regression and antitumor responses in vivo. Nature Med 1998; 3: 625-631.
5. Hubbard S, Wei L, Ellis L, Hendrickson W. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 1994; 372: 746-754.
6. Rosnet O, Buhring HJ, deLapeyriere O, Beslu N, Lavagna C, Marchetto S, Rappold I, Drexler HG, Birg F, Rottapel R, Hannum C, Dubreuil P, Birnbaum D. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol 1996; 95: 218-223.
7. Lavagna-Sévenier C, Marchetto S, Birnbaum D, Rosnet O. FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998; 12: 301-310.
8. Lavagna-Sévenier C, Marchetto S, Birnbaum D, Rosnet O. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem 1998; 273: 14962-14967.
9. Gotoh N, Tojo A, Shibuya M. A novel pathway from phosphorylation of tyrosine residues 239/240 of SHC, contributing to suppress apoptosis by IL-3. EMBO J 1996; 15: 6197-6204.
10. Gotoh N, Toyoda M, Shibuya M. Tyrosine phosphorylation sites at amino acids 239 and 240 of SHC are involved in epidermal growth factor-induced mitogenic signaling that is distinct from Ras/mitogen-activated protein kinase activation. Mol Cell Biol 1997; 17: 1824-1831.
11. Rottapel R, Turck C, Casteran N, Liu X, Birnbaum D, Pawson T, Dubreuil P. Substrate specificities and identification of a putative binding site for Pl3K in the carboxy tail of murine Flt3 receptor tyrosine kinase. Oncogene 1994; 9: 1755-1765.
12. Le Dréan E, Vély F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol 1998; 28: 264-276.
13. Blaikie P, Fournier E, Dilworth S, Birnbaum D, Borg JP, Margolis B. The role of the Shc phosphotyrosine interaction/ phosphotyrosine binding domain and tyrosine phosphorylation sites in polyoma middle T antigen-mediated cell transformation. J Biol Chem 1997; 272: 20671-20677.
14. Fournier E, Blaikie P, Rosnet O, Margolis B, Birnbaum D, Borg JP. Role of tyrosine residues and protein interaction domains of SHC adaptor in VEGF receptor 3 signaling. Oncogene 1999; 18: 507-514.
15. Bonfini L, Migliaccio E, Pelicci G, Lanfrancone L, Pelicci PG. Not all Shc's roads leads to Ras. Trends Biochem Sci 1996; 21: 257-261.
16. van der Geer P, Wiley S, Gish G, Pawson T. The Shc adaptor protein is highly phosphorylated at conserved, twin residues (Y239/240) that mediate protein-protein interactions. Curr Biol 1996; 6: 1435-1444.
17. Pradhan M, Coggeshall KM. Activation-induced bi-dentate interaction of SHIP and Shc in B lymphocytes. J Cell Biochem 1997; 67: 32-42.
18. Lamkin TD, Walk SF, Liu L, Damen JE, Krystal G, Ravichandran KS. Shc interaction with Src homology 2 domain containing inositol phosphatase (SHIP) in vivo requires the Shc-phosphotyrosine binding domain and two specific phosphotyrosines on SHIP. J Biol Chem 1997; 272: 10396-10401.
19. Liu L, Damen JE, Ware MD, Krystal G. Interleukin-3 induces the association of the inositol 5-phosphatase SHIP with SHP2. J Biol Chem 1997; 272: 10998-11001.
20. Beslu N, LaRose J, Casteran N, Birnbaum D, Lecocq E, Dubreuil P, Rottapel R. Phosphatidylinositol-3′ kinase is not required for mitogenesis or internalization of the Flt3/Flk2 receptor tyrosine kinase. J Biol Chem 1996; 271: 20075-20081.
21. Papayannopoulou T, Nakamoto B, Andrews R, Lyman D, Lee M. In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor. Blood 1997; 90: 620-629.
22. Sudo Y, Shimazaki C, Ashihara E, Kikuta T, Hirai H, Sumikuma T, Yamagata M, Goto H, Inaba T, Fujita N, Nakagawa M. Synergistic effect of FLT-3 ligand on granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice. Blood 1997; 89: 3186-3191.
23. Maraskovsky E, Brasel K, Teepe M, Roux E, Lyman S, Shortman K, McKenna H. Dramatic increase in the numbers of functionally mature dendritic cells in FLT3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962.
24. Harmer S, DeFranco A. Shc contains two Grb2 binding sites needed for efficient formation of complexes with SOS in B lymphocytes. Mol Cell Biol 1997; 17: 4087-4095.
25. Zhou M-M, Ravichandran K, Olejniczak E, Petros A, Meadows R, Sattler M, Harlan J, Wade W, Burakoff S, Fesik S. Structure and ligand recognition of the phosphotyrosine binding domain of Shc. Nature 1995; 378: 584-592.
26. Ravichandran K, Zhou M-M, Pratt J, Harlan J, Walk S, Fesik S, Burakoff S. Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo. Mol Cell Biol 1997; 17: 5540-5549.
27. Yajnik V, Blaikie P, Bork P, Margolis B. Identification of residues within the SHC phosphotyrosine binding/phosphotyrosine interaction domain crucial for phosphopeptide interaction. J Biol Chem 1996; 271: 1813-1816.
28. van der Geer P, Pawson T. The PTB domain: a new protein module implicated in signal transduction. Trends Biochem Sci 1995; 20: 277-280.
29. Sato K, Gotoh N, Otsuki T, Kakumoto M, Aoto M, Tokmakov A, Shibuya M, Fukami Y. Tyrosine residues 239 and 240 of SHC are phosphatidylinositol 4,5-biphosphate-dependent phosphorylation sites by c-Src. Biochem Biophys Res Commun 1997; 240: 399-404.
30. Barone MV, Courtneidge S. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 1995; 378: 708-712.
31. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Onc 1993; 4: 595-613.
32. Chen H, Chang S, Trub T, Neel B. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol 1996; 16: 3685-3697.
33. Kozlowski M, Larose L, Lee F, Le DM, Rottapel R, Siminovitch K. SHP-1 binds and negatively modulates the c-Kit receptor by interaction with tyrosine 569 in the c-Kit juxtamembrane domain. Mol Cell Biol 1998; 18: 2089-2099.
34. Paulson R, Vesely S, Siminovitch K, Bernstein A. Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase. Shp1. Nat Genet 1996; 13: 309-315.
35. Miyake S, Lupher M, Drucker B, Band H. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor a. Proc Natl Acad Sci USA 1998; 95: 7927-7932.
36. Klingmüller U, Lorenz U, Cantley L, Neel B, Lodish H. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995; 80: 729-738.
37. Murphy M, Schnall R, Venter D, Barnett L, Bertoncello I, Thien C, Langdon W, Botwell D. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol 1998; 18: 4872-4882.
38. O'Rourke L, Tooze R, Fearon DT. Co-receptors of B lymphocytes. Curr Opin Immunol 1997; 9: 324-329.
39. Bolland S, Pearse R, Kurosaki T, Ravetch J. SHIP modulates immune receptor responses by regulating membrane association of Btk. Immunity 1998; 8: 509-516.
40. 3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP mediated inhibitory signals. EMBO J 1998; 17: 1961-1972.
41. ship, a signal transduction molecule with inositol polyphosphate-5-phosphatase activity. Genes Dev 1996; 10: 1084-1095.
42. Damen JE, Liu L, Rosten P, Humphries RK, Jefferson AB, Majerus PW, Krystal G. The 145-kDa protein induced to associate with Sch by multiple cytokines is an inositol tetraphosphate and phosphatidylinositol 3,4,5-triphosphate 5-phosphatase. Proc Natl Acad Sci USA 1996; 93: 1689-1693.
43. Ravichandran KS, Lee KK, Songyang Z, Cantley L, Burn P, Burakoff S. Interaction of Shc with the zeta chain of the T cell receptor upon T cell activation. Science 1993; 262: 902-905.
44. Saxton TM, Van Hostveen D, Botwell R, Aebersold R, Gold MR. B cell antigen receptor cross-linking induces tyrosine phosphorylation of the p21ras oncoprotein activator SHC and SOS1 as well as assembly of complexes containing SHC, GRB-2, mSOS1, and a 145-kD tyrosine-phosphorylated protein. J Immunol 1994; 153: 623-636.
45. Liu L, Damen JE, Hughes MR, Babic I, Jirik FR, Krystal G. The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis. J Biol Chem 1997; 272: 8983-8988.
46. Gervais F, Chow L, Lee J, Branton P, Veillette A. The SH2 domain is required for stable phosphorylation of p56lck at tyrosine 505, the negative regulatory site. Mol Cell Biol 1993; 13: 7112-7121.
47. Rotin D, Margolis B, Mohammadi M, Daly R, Daum G, Li N, Fisher E, Burgess W, Ullrich A, Schlessinger J. SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for the SH2 domains of phospholipase C gamma. EMBO J 1992; 11: 559-567.
48. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, Forni G, Nicoletti I, Pawson T, Pelicci PG. A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 1992; 70: 93-104.
49. Lanfrancone L, Pelicci G, Brizzi MF, Arouica MG, Casciari C, Giuli S, Pegoraro L, Pawson T, Pelicci PG. Overexpression of the Shc proteins potentiates the proliferative response to the granulocyte-macrophage colony-stimulating factor and recruitment of Grb2/Sos and Grb2/p140 complexes to the b receptor subunit. Oncogene 1995; 10: 907-917.
50. Downward J. Ras signalling and apoptosis. Curr Opin Gen Dev 1998; 8: 49-54.
51. Terada K, Kaziro Y, Satoh T. Ras is not required for the interleukin 3-induced proliferation of a mouse pro-B cell line, Baf3. J Biol Chem 1995; 270: 27880-27886.
52. Tridandapani S, Kelley T, Cooney D, Pradhan M, Coggeshall KM. Negative signaling in B cells: SHIP Grbs Sch. Immunol Today 1997; 18: 424-427.